Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has received official minutes from a Type C meeting with the U.S. Food and Drug Administration (FDA) that support the company's plans for an adaptive Phase 2 field study of TNX-4800, its long-acting anti-OspA monoclonal antibody candidate designed to prevent Lyme disease. The announcement, made via press release, indicates that the planned randomized, placebo-controlled study is expected to enroll approximately 3,300 adults over two Lyme disease seasons to evaluate prevention through six months after dosing. Manufacturing of the investigational product is on track for delivery to study sites in the first quarter of 2027.
TNX-4800 is being developed as a seasonal immunopreventative administered as two subcutaneous injections three months apart, with the potential to provide protection throughout the U.S. Lyme disease season. This approach could offer a new preventive option for a disease that affects hundreds of thousands of people annually in the United States. The FDA's feedback is a critical step in advancing the clinical development of this candidate.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. The company's flagship medicine, TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), is the first new treatment for fibromyalgia in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® SymTouch® and Tosymra®.
The company is also maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. Additionally, the CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. In the immunology space, Tonix is advancing TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
The FDA's support for the Phase 2 study design is a significant milestone for Tonix, as it de-risks the clinical pathway for TNX-4800. For industry observers, this development underscores the growing interest in monoclonal antibodies for infectious disease prevention. If successful, TNX-4800 could become a seasonal preventive measure, potentially reducing the burden of Lyme disease, which is the most common vector-borne disease in the U.S.
The implications for the biotechnology sector are notable. A preventive monoclonal antibody for Lyme disease would address a significant unmet medical need, as current prevention relies primarily on tick avoidance and, in some cases, antibiotic prophylaxis after tick bites. The six-month protection offered by TNX-4800 could be particularly valuable for individuals in high-risk occupations or regions with prolonged tick exposure.
Tonix's progress with TNX-4800 also highlights the company's commitment to expanding its immunology pipeline beyond its CNS focus. The company's ability to secure FDA feedback early in development may streamline future trials and potentially accelerate time to market.
For more information on Tonix Pharmaceuticals, visit the company's newsroom at https://ibn.fm/TNXP. The full press release is available at https://ibn.fm/pe0eP.
Investors and stakeholders will be watching for further developments as the Phase 2 study progresses. The delivery of investigational product to study sites in Q1 2027 marks a key timeline to monitor.
